Broadcast Tuesday 18th August 2026
ADHD Aware is a UK charity with years of experience working directly with and supported tens of thousands of people affected by ADHD. We know how difficult it can be and the negative effect this condition can have on mental and physical health, and why we fight for early and professional diagnosis for anyone considering that they may have ADHD, ADHD Aware was disappointed at the oversimplified, irresponsible and potentially damaging impact of this documentary. The flawed approach, lack of objectivity and significant limits of the research methods ultimately discredits and undermines its own conclusions.
We’d like to share the responses by two of the experts we work with closely at ADHD Aware UK. Dr Jess Eccles is ADHD Aware’s patron and a Reader (Associate Professor) in Brain-Body Medicine at the Sussex Medical School. Dr Eccles wrote a detailed response to the show, which we reproduce in full below. Karen Doherty is a Psychotherapist specialising in neurodivergent couples, and has worked with us on our Couples courses. We are sharing her response to the show as well.
Our Patron, Dr Jess Eccles, Reader (Associate Professor) in Brain-Body Medicine, at Brighton and Sussex Medical School:
“What can the Mason ‘experiment’ actually tell us?
Nothing that would count as evidence in any scientific sense, and the programme’s own footage inadvertently demonstrates why. What is presented as an experiment is a single, unblinded, uncontrolled case study, filmed for television, in which a family who had already decided to try coming off medication were coached through six simultaneous lifestyle changes at once: medication withdrawal, removal of all screens and gaming devices, a new diet (no ultra-processed food, no sugary sweets, increased protein), unnamed nutritional supplements, a yoga routine, and substantially more one-to-one outdoor time and parental attention.
With six variables changing together, there is no way to attribute anything that follows to any one of them, let alone to establish that ADHD itself is not real. This is Mill’s basic requirement for causal inference — change one thing at a time — and the film violates it comprehensively. On top of that:
- N = 1. A single child’s response, however filmed and narrated, cannot generalise to a condition affecting an estimated 3–5% of the population; it isn’t a study, it’s an anecdote.
- No control condition and no blinding. Everyone involved — Mason, his mother, his teacher, the presenter — knew medication had been stopped and knew cameras were rolling, which is a well-documented recipe for expectancy and observer effects (the Hawthorne effect) in both directions.
- A large, simultaneous increase in positive attention. The family spent “more time… together as a family,” with a coach, a nutritionist and a film crew newly present in the house. It would be surprising if a child’s mood and behaviour did not improve for a period given that much additional structured attention, irrespective of medication status.
- The follow-up period was too short, and the programme’s own data undercuts its conclusion. By week five, the child’s teacher was recording him as “more disruptive, more talkative, more fidgety, disengaged,” struggling to complete work he had previously managed, and his mother described him needing “normal breaks” and getting frustrated that he “can’t do it” anymore. That is the clinical picture the medication had been controlling, re-emerging on cue — which is closer to evidence for the diagnosis than against it.
A responsible interpretation is that this sequence shows what child ADHD services already know: structure, routine, exercise, nature and reduced screen use are good for most children’s regulation and mood, medication changes are naturally followed by a return of pre-treatment symptoms once drug levels fall, and a single family’s six-week experience, filmed for entertainment, cannot answer a scientific question about whether a condition with a 70–80% heritability and a 200-year documented history is “real.” Using it as the narrative spine of a documentary that concludes ADHD is a myth is a serious misuse of what is, at best, a human-interest vignette.
Is there evidence that ultra-processed food, sugar, screens or time in nature cause ADHD (or its symptoms)?
1) Diet and sugar
There is a growing evidence base linking higher intake of ultra-processed food with more ADHD symptoms in cross-sectional and cohort studies, and some data associating sugar intake with hyperactivity ratings. This is worth taking seriously as one of several modifiable factors that can affect how symptomatic a child appears. But nearly all of this literature is observational and correlational, and the studies themselves are careful to flag the obvious confounds the documentary ignores: children with more impulsive, reward-driven eating patterns (a recognised feature of ADHD itself) tend to select more processed, sugary food, so the causal arrow plausibly runs partly from ADHD traits to diet, not only the other way round; family income, parental mental health, sleep and general chaos in the home independently predict both diet quality and behavioural symptoms; and no randomised controlled trial has shown that removing ultra-processed food or sugar from an already-diagnosed child’s diet resolves ADHD. NICE’s own guideline does not list dietary elimination as a treatment for ADHD; it recommends a healthy, balanced diet for all children as general good practice, and suggests a formal dietary assessment only where a clear food–symptom link is reported by the family, with any exclusion diet supervised by a dietitian — a world away from the blanket claim made in the film that sugar and processed food are “implicated” in causing the disorder.
2) Screens
The claim that any child “100% guaranteed” would look ADHD-like after screen use is not supported by the research. Large longitudinal studies and a 2022 Mendelian randomisation analysis — a design specifically built to test causality rather than mere association — have found no good evidence that early screen exposure causally produces later inattention or hyperactivity symptoms; where correlations exist, more recent work using genetically informed and cross-lagged designs points toward children with higher pre-existing ADHD traits being drawn to screens (again, reverse causation), rather than screens creating the traits. Excess recreational screen time has plenty of other reasons to be limited in children — sleep, physical activity, mood — but the causal claim made in the documentary outstrips what the data will support. ADHD existed before screens.
3) Nature, exercise and structure
Short exposure to green space and physical activity does measurably improve attention and mood in the general population, including in children with ADHD — this is well replicated. But an effect that improves attention in everyone is a marker of general wellbeing benefit, not evidence that the underlying condition doesn’t exist; the same is true of exercise for depression, which helps substantially without meaning depression isn’t real. NICE recommends exercise, sleep hygiene and structured routines as sensible adjuncts alongside — not instead of — evidence-based treatment for ADHD, precisely because they help general functioning without being disease-modifying.
What is the evidence base for ADHD medication — efficacy, safety and side effects such as reduced energy or feeling ‘less fun’?
ADHD medications (stimulants such as methylphenidate and lisdexamfetamine, and non-stimulants such as atomoxetine and guanfacine) are among the most extensively studied classes of drugs in psychiatry. Cochrane reviews and large meta-analyses — spanning well over 100 randomised, placebo-controlled trials and tens of thousands of participants — consistently show moderate-to-large effect sizes for reducing core inattentive, hyperactive and impulsive symptoms, comparing favourably with effect sizes for many accepted treatments in general medicine. Beyond symptom scores, register and cohort studies (not just short trials) link treatment with real-world functional outcomes: better academic attainment, fewer unintentional injuries and road traffic accidents, lower rates of substance misuse and criminal offending, and — importantly given how the film frames medication as purely cosmetic — a reduction in suicide attempts, an outcome that matters given adults with untreated ADHD carry a substantially elevated risk of self-harm.
None of this means medication is free of downsides, and the film is right that side effects are real and should be discussed honestly: reduced appetite, sleep disruption, increased heart rate and blood pressure (requiring monitoring), and in children, a modest, usually reversible slowing of growth that is why height and weight are tracked at every review. The subjective experience some patients and families describe — feeling flatter, “less fun,” less spontaneous — is a recognised phenomenon, sometimes linked to dose being higher than needed, and is exactly the kind of individual response that a proper titration and review process (which NICE mandates) is designed to catch and adjust for. It is a legitimate conversation to have with a prescriber about dose and choice of medication; it is not evidence that the underlying difficulty being treated is fictional, any more than a patient feeling drowsy on an antihistamine means their hay fever isn’t real. Every effective medicine trades a benefit against some cost, and ADHD medication is monitored, titrated and reviewed — including at least annually, with an explicit discussion of whether to continue — specifically because that trade-off is taken seriously in UK practice.
Brain imaging, ‘no biological marker’ and the claim ADHD ‘doesn’t exist in the material reality of the brain and body’
The documentary conflates two different claims that need separating: (a) no brain scan can currently diagnose ADHD in an individual, which is true; and (b) therefore there is no biological basis to ADHD and it doesn’t exist in the brain or body, which does not follow and is contradicted by a large body of evidence.
On (a): this is true of the overwhelming majority of psychiatric diagnoses, and of a great many physical ones — migraine, irritable bowel syndrome, fibromyalgia, most epilepsy, functional cardiac symptoms and chronic pain conditions are all diagnosed clinically, without a scan or blood test that can pick out one individual’s brain or body as abnormal. Group-level statistics not translating into an individual diagnostic test is a limitation of current imaging resolution and inter-individual variability, not proof of non-existence — and it is worth noting explicitly that this is exactly what Professor Rubia herself says in the interview (“based on group statistics… there are differences”), immediately before the film’s narration reframes that as evidence there is nothing there at all.
On (b): at group level, the evidence for a neurobiological basis is substantial and long-standing. The ENIGMA-ADHD mega-analysis (Hoogman et al., Lancet Psychiatry, 2017), pooling MRI data from over 3,200 participants across dozens of international sites, found significantly smaller volumes in several subcortical brain regions (including the amygdala, caudate, putamen, nucleus accumbens and hippocampus) in people with ADHD compared with controls, effects most pronounced in childhood. Later ENIGMA work extended this to cortical thickness and surface area. Twin and family studies put heritability at roughly 70–80%, among the highest of any psychiatric condition and comparable to height; genome-wide association studies have identified specific common genetic variants associated with ADHD, and these findings replicate. The 2021 International Consensus Statement on ADHD, signed by over 80 senior researchers across 27 countries and summarising more than 200 evidence-based conclusions drawn from studies of hundreds of thousands of participants, states plainly that claims ADHD does not exist are “contradicted by a large body of research.” None of this means every person with the diagnosis has a scan that looks different — individual variability is large, exactly as Professor Rubia says — but the leap from “can’t be read off one scan” to “doesn’t exist in the material reality of the brain and body” is not a scientific conclusion; it is a rhetorical one, and it sits uneasily even with the researcher’s own published body of work over thirty years of imaging ADHD.
Is ADHD a ‘social construct’, and do we agree?
This is really two claims wearing one label, and the documentary trades on the ambiguity between them. In one sense, yes: the threshold at which a pattern of inattention or impulsivity becomes a diagnosable “disorder” is set by expert consensus, reviewed periodically, and inevitably involves judgement about where normal human variation tips into clinically significant impairment. That is true of every diagnostic category in medicine — the blood pressure at which we call someone hypertensive, the BMI at which we call someone obese, the mood-symptom count for major depression — all of these are constructed thresholds on continuous human variation, agreed by clinicians and revised as evidence accumulates. Describing the threshold as constructed is banal, not damning.
Where the documentary goes further, and where the evidence does not support it, is the claim that this makes the underlying difficulty, and the biological differences and heritability that predispose to it, not real — “a subjective imagination.” Genes, twin-study heritability and group-level brain differences are not something a committee invents; the diagnostic label organising them for clinical use is a human construction layered on top of something that pre-exists it. Conflating “the category has a constructed boundary” with “the phenomenon inside the boundary is fake” is a common but identifiable logical slip, and it is the same move critics have made, unsuccessfully, against most other psychiatric diagnoses over the decades. So: we agree the diagnostic threshold is a construct, in the same limited sense every diagnostic threshold in medicine is; we disagree that ADHD’s traits, distress, impairment and biology are therefore not real.
Is it safe to stop ADHD medication ‘cold turkey’, and what should someone who’s considering it do?
No — not without medical involvement, and the programme’s own framing (“coming off the drugs for Mason is going to be really difficult because he’s coming off cold turkey”) already flags the risk it then treats as an incidental side detail. Stopping stimulant medication abruptly is associated with rebound symptoms — a resurgence of inattention, irritability and emotional reactivity that can be more pronounced than the original baseline for a period — as the brain readjusts after prolonged exposure. NICE’s evidence review on withdrawal (part of guideline NG87) found that stopping medication is consistently associated with a return or worsening of ADHD symptoms, particularly in children and young people, and recommends any decision to stop is made collaboratively with the prescriber, ideally as part of a planned, gradual taper with monitoring, and not undertaken unilaterally.
Anyone who has watched the programme and is now considering stopping their own or their child’s medication should be advised, clearly and without alarm, to speak to their prescriber first rather than stop abruptly: to review, with that clinician, why the medication was started and what it is currently achieving; to plan any change as a supervised, gradual reduction rather than an overnight stop, so response can be monitored and rebound managed; and to know that deciding to pause or stop medication is a legitimate and normal part of ongoing ADHD care — NICE requires an annual review that explicitly includes discussing whether to continue — but it works far better, and more safely, as a planned conversation than as a response to a television programme.
On NICE and ‘drug holidays’ specifically
It is true that NICE guidance discusses planned treatment breaks (“drug holidays”), and it is worth being precise about what that actually means, because the film’s use of “cold turkey” bears little resemblance to it. NICE’s own evidence review found only very limited, low-quality evidence for planned breaks (the main study examined weekend-only breaks in children), concluded any apparent benefit likely reflected the limitations of that evidence rather than a genuine advantage, and specifically cautioned that encouraging breaks risks worse overall adherence to treatment. Where breaks are used in practice, they are specialist-led, planned, reviewed, and historically mostly relevant to monitoring growth in children on long-term stimulant treatment — not a general recommendation to periodically stop, and certainly not a template for a full, unsupervised six-week discontinuation triggered by a TV experiment.
Was a video-call interview a standard diagnostic assessment?
Remote (video) consultation is an accepted mode of delivery in NHS and GMC practice and is not, by itself, the issue — what matters is the content and thoroughness of the assessment, not the medium. NICE, the Royal College of Psychiatrists’ good-practice guidance (CR235) and the UK Adult ADHD Network’s quality standard converge on what a proper assessment requires: a full clinical and psychosocial history, a developmental history reaching back to childhood, ideally corroborated by a collateral informant who knew the person as a child (a parent, older sibling, or old school reports) and someone who knows them now, a semi-structured interview built around concrete real-life examples rather than yes/no ticks, validated rating scales interpreted in clinical context rather than scored in isolation, a mental state examination, and screening for the co-occurring conditions — anxiety, depression, autism, substance use — that affect the majority of adults with ADHD. This typically takes two hours or more of clinical time. An ADHD diagnosis should never rest on a questionnaire or a single self-report conversation alone; this is the RCPsych’s own stated position, including in its response to this documentary.
The single assessment shown in the film cannot be judged reliably from the sequence, but the process it depicts — without visible collateral history-taking, developmental record review or comorbidity screening — is not, on its face, meeting that standard, and £1,200 for 45 minutes to an hour is a red flag for thoroughness regardless of the outcome. That is a genuine and serious issue, but it is an argument for scrutinising and improving assessment quality — exactly what the RCPsych, the ADHD Taskforce and CQC are all independently calling for — not an argument that the diagnostic category itself is invalid. A bad assessment for a real condition is still a bad assessment; it doesn’t retroactively make the condition fictional. There was no discussion of how the functional impairment was discussed or handled?
What do we know about the validity of diagnoses from private clinics?
Explosive, evidenced growth in demand has met chronically under-resourced NHS adult ADHD services — the Independent ADHD Taskforce found adults waiting up to eight years for assessment in some areas — and private clinics have filled that gap at scale; NHS commissioners themselves now spend heavily on independent providers to manage waiting lists. This creates a genuine two-tier problem the RCPsych, CQC and the Taskforce have all flagged: variable quality, weak regulatory oversight (the CQC has faced criticism for inconsistent inspection of neurodevelopmental services, with some providers going uninspected for long periods), and a real financial incentive for high-volume providers to shorten assessments. Concerns about profit-driven, corner-cutting private providers are legitimate and worth investigating journalistically.
What that evidence does not show is that private-sector diagnosis is systematically wrong in one direction. Poor-quality, rushed assessment can drive both over- and under-diagnosis — a superficial tick-box process can wrongly diagnose someone who doesn’t meet threshold, and can equally wrongly clear someone who does, particularly women and adults whose presentation doesn’t match the stereotyped hyperactive-boy picture and who are already known to be under-recognised. The Taskforce’s own conclusion, drawing on national and international prevalence data, is that England has been under-diagnosing relative to comparable countries and to the 3–5% prevalence estimate, not over-diagnosing overall. The right response to variable private-sector quality is regulation, published quality standards and NHS capacity — all things the Taskforce report recommends — not a conclusion that the underlying diagnosis is a myth.
Karen Doherty, Specialist Neurodivergent couples’ psychotherapist:
“ADHD: IS IT A MYTH? What a title. Guaranteed to get half the nation watching. But after watching the programme, I was left wondering: where was the myth? Mason returned to medication because ADHD was affecting his executive functioning and academic work. The medication helped him concentrate.
Myth? No.
Reducing screens, improving nutrition, increasing movement and getting children into nature can improve attention and regulation. Of course it can. For many of us.
But that doesn’t mean ADHD doesn’t exist.
Is ADHD assessment in the UK becoming increasingly commercialised because an overwhelmed NHS cannot meet demand?
Yes — and we absolutely should be talking about it.
Does our education system need to change to accommodate children who learn, process and regulate differently?
Absolutely.
But again, none of this makes ADHD a myth.
There are legitimate questions about diagnosis, medication, commercialisation, lifestyle and education. Let’s have those conversations. But questioning how we diagnose and manage ADHD is very different from questioning whether ADHD exists. A provocative title makes good television. But controversy isn’t evidence.”